Genetic testing, such as 23andMe, has been approved by the FDA for direct-to-consumer genetic testing. However, this type of testing has not been approved to predict rheumatic diseases. Research is being conducted to determine if this type of direct-to-consumer genetic testing will eventually be beneficial in the field of rheumatology for disease diagnosis and prediction.
Read the source article at healio.com
What are your thoughts on direct-to-consumer genetic testing? Share your stories, thoughts, and hopes with the Patient Worthy community!
